AbbVie presents ABBV-466 Crohn’s disease data
The company reported higher endoscopic remission rates with its dual-targeting therapy than with either anti-IL-23 or anti-α4β7 monotherapy in moderate to severe Crohn’s disease.
The company reported higher endoscopic remission rates with its dual-targeting therapy than with either anti-IL-23 or anti-α4β7 monotherapy in moderate to severe Crohn’s disease.